SCCA Clinical Studies: Phase 1 Program
|Closed||Tumors Characterized by Genetic Abnormalities of ALK||Phase I||
This study will assess the safety and early efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).
|Ages Eligible for Study:||18 Years and older|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
• Tumor must be confirmed to be ALK positive
- Active pancreatitis
- Active or chronic liver disease
Other protocol-defined inclusion/exclusion criteria may apply
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.